Cardiff Oncology, Inc. (CRDF)
Company Info
| ISIN | US14147L1089 |
|---|---|
| CUSIP | 14147L108 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $151.62M |
|---|---|
| EPS | -$0.93 |
| Revenue (TTM) | $488.00K |
| Gross Profit (TTM) | -$26.72M |
| EBITDA (TTM) | -$45.01M |
| Year Range | $0.94 - $6.42 |
| Target Price | $10.50 |
| Short % | 9.19% |
| Short Ratio | 3.33 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: CRDF vs. ATXS
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Cardiff Oncology, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Cardiff Oncology, Inc. had a return of 145.27% year-to-date (YTD) and 113.53% in the last 12 months. Over the past 10 years, Cardiff Oncology, Inc. had an annualized return of -35.17%, while the S&P 500 had an annualized return of 10.99%, indicating that Cardiff Oncology, Inc. did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 145.27% | 11.18% |
| 1 month | -19.33% | 5.60% |
| 6 months | 202.50% | 17.48% |
| 1 year | 113.53% | 26.33% |
| 5 years (annualized) | 3.34% | 13.16% |
| 10 years (annualized) | -35.17% | 10.99% |
Monthly Returns
The table below presents the monthly returns of CRDF, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 5.41% | 13.46% | 201.69% | -18.35% | 145.27% | ||||||||
| 2023 | 27.86% | -3.35% | -4.62% | 5.45% | -7.47% | -8.70% | 20.41% | 3.95% | -24.46% | -23.02% | 14.95% | 20.33% | 5.71% |
| 2022 | -43.76% | -20.41% | -7.81% | -45.97% | 0.75% | 62.96% | 0.45% | 21.72% | -42.75% | 5.84% | -2.45% | -11.95% | -76.71% |
| 2021 | -34.41% | -12.37% | -10.44% | 7.24% | -15.41% | -20.83% | -20.00% | 37.78% | -9.14% | -11.86% | -4.26% | 6.94% | -66.59% |
| 2020 | 29.03% | -14.37% | -26.28% | 22.77% | 99.19% | 102.83% | -4.19% | 65.42% | 78.72% | 11.49% | 56.19% | -27.20% | 1,350.81% |
| 2019 | 26.42% | -20.15% | 16.82% | -6.93% | -17.48% | -13.19% | -30.00% | 6.86% | -19.25% | 19.87% | -20.99% | -13.29% | -61.01% |
| 2018 | -16.13% | 15.38% | 16.67% | -20.00% | -14.29% | -73.26% | 1.30% | 5.13% | -0.00% | -14.63% | 0.00% | -24.29% | -85.75% |
| 2017 | -4.76% | -2.50% | -41.03% | -19.13% | -31.18% | 96.87% | -35.71% | -18.52% | 10.61% | -2.74% | -15.49% | -48.33% | -85.24% |
| 2016 | -32.59% | 41.48% | -9.71% | -13.55% | 31.09% | -14.04% | 24.28% | -12.79% | -8.55% | -23.16% | -15.94% | -27.59% | -61.11% |
| 2015 | 51.16% | -13.08% | 20.53% | 13.80% | 41.42% | -7.39% | -22.36% | -24.49% | -4.37% | -24.25% | 49.88% | -16.41% | 25.58% |
| 2014 | 1.05% | 8.62% | -9.05% | -1.75% | -32.86% | -7.41% | -9.71% | 84.81% | -21.58% | 9.39% | -8.38% | -6.32% | -25.09% |
| 2013 | -0.43% | -10.87% | 1.79% | -5.43% | 17.06% | 0.87% | 17.02% | 0.24% | -12.44% | -11.28% | -10.52% | 0.70% | -17.17% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current risk-adjusted rank of CRDF is 78, placing it in the top 22% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
CRDF (Cardiff Oncology, Inc.)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Cardiff Oncology, Inc. (CRDF) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Cardiff Oncology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cardiff Oncology, Inc. was 99.96%, occurring on Mar 18, 2020. The portfolio has not yet recovered.
The current Cardiff Oncology, Inc. drawdown is 99.81%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.96% | Jun 9, 2005 | 3719 | Mar 18, 2020 | — | — | — |
| -42.53% | Nov 29, 2004 | 76 | Mar 17, 2005 | 57 | Jun 8, 2005 | 133 |
| -5.88% | Nov 18, 2004 | 3 | Nov 22, 2004 | 1 | Nov 23, 2004 | 4 |
| -1.32% | Oct 8, 2004 | 1 | Oct 8, 2004 | 17 | Nov 2, 2004 | 18 |
Volatility
Volatility Chart
The current Cardiff Oncology, Inc. volatility is 29.90%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
| Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
| Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |